Skip to content
Home/Companies/Biotech/HTL
HTL

HTL

Biotech·France·Active·9yr hold
Entry
2017
Hold
9yr
Status
Active

Who owns HTL?

HTL is a French Biotech company, currently owned by Naxicap Partners since 2017.

Hand-verified · updated 2026-04-21

Open JSON · CC-BY
Naxicap Partners
Investor
Naxicap Partners
NIO I · 2017 · Buyout

Key facts

HQFrance
SectorBiotech
Websitehtlbiotech.com

More from NIO I

Other portfolio companies in the same fund.

Dental Monitoring
Dental Monitoring
Exited 2021
HealthTechFrance· 2019
to Merieux Equity Partners / Vitruvian Partners
Emera
Active
HealthcareFrance· 2019
Executive IT
Exited 2023
IT ServicesFrance· 2019
to Bechtle AG
Finophta
Exited 2019
SoftwareFrance· 2019
to EYE-Q
KEYS ASSET MANAGEMENT
Keys Asset Management
Active
Business ServicesFrance· 2019
MORIA
Moria
Active
MedTechFrance· 2019

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns HTL?

HTL is currently owned by Naxicap Partners, through NIO I, since 2017.

When did Naxicap Partners acquire HTL?

Naxicap Partners acquired HTL in 2017.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue